Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors

Citations

WEB OF SCIENCE

2
Citations

SCOPUS

5

초록

Introduction: Patients with hypertension and additional cardiovascular risk factors pose a challenge by requiring more intensive blood pressure (BP) control. Single-pill combination (SPC) therapy can benefit these patients by improving medication adherence. Methods: This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors. BP control rates, defined as the percentage of patients achieving systolic BP (SBP)\ 130 mmHg and diastolic BP (DBP)\ 80 mmHg for intensive BP control, and\ 140 mmHg and\ 90 mmHg, respectively, for standard BP control, were investigated across various cardiovascular risk groups, along with changes in SBP and DBP from baseline to week 24. Results: The most prevalent cardiovascular risk factor was age (>= 45 years in men, >= 55 years in women, 86.1%), followed by cardiovascular diseases (64.4%), dyslipidemia (53.7%), body mass index >= 25 kg/m(2) (53.5%), and diabetes mellitus (DM) (46.3%). Switching to O/A/H showed significant BP reduction, with a mean change of - 17.8 mmHg/- 9.3 mmHg in SBP/ DBP within 4 weeks. The intensive BP control rate was 41.4% (95% confidence interval [CI] 39.5, 43.4), and the standard BP control rate was 73.3% (95% CI 71.5, 75.1), with better control rates in the risk age group (43.1% and 74.1%, respectively) and cardiovascular disease group (42.0% and 73.8%, respectively). The DM group had relatively lower control rates (37.5% for intensive control and 69.4% for standard control). Common adverse drug reactions included dizziness (2.91%), hypotension (1.51%), and headaches (0.70%). Conclusion: The SPC therapy of O/A/H caused a rapid and sustained reduction in SBP/DBP in patients' hypertension and additional cardiovascular risk factors. The therapy was safe and well tolerated.

키워드

Olmesartan-based combination therapySingle-pill combinationPatients with hypertension and additional cardiovascular risk factorsReal-world effectiveness of blood pressure controlBLOOD-PRESSURE CONTROLOLMESARTAN MEDOXOMILTHERAPYMANAGEMENTAMLODIPINEHYDROCHLOROTHIAZIDEEFFICACYOUTCOMES
제목
Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors
저자
Oh, JaewonKim, WonhoKim, Gee-HeeKim, Hack-LyoungPark, Sang-DonMin, Kyung WanHyun, DongkeunHong, Jun HwaLim, SooShin, Jinho
DOI
10.1007/s12325-023-02632-9
발행일
2023-11
유형
Article
저널명
Advances in Therapy
40
11
페이지
4817 ~ 4835